Zacks: Analysts Anticipate Evoke Pharma Inc (EVOK) Will Post Earnings of -$0.17 Per Share
Equities research analysts forecast that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings per share (EPS) of ($0.17) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evoke Pharma’s earnings, with estimates ranging from ($0.19) to ($0.14). Evoke Pharma posted earnings per share of ($0.14) in the same quarter last year, which would suggest a negative year over year growth rate of 21.4%. The company is expected to report its next earnings results on Monday, May 21st.
According to Zacks, analysts expect that Evoke Pharma will report full year earnings of $0.10 per share for the current fiscal year, with EPS estimates ranging from ($0.47) to $1.16. For the next year, analysts anticipate that the business will post earnings of $0.51 per share, with EPS estimates ranging from ($0.83) to $1.85. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at $2.07 on Tuesday. Evoke Pharma has a 52 week low of $1.85 and a 52 week high of $4.09.
Several large investors have recently modified their holdings of EVOK. Creative Planning acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $226,000. B. Riley Financial Inc. acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $249,000. 683 Capital Management LLC acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $258,000. Deutsche Bank AG acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $452,000. Finally, Vanguard Group Inc. increased its position in shares of Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. 18.42% of the stock is owned by hedge funds and other institutional investors.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.